TP53 and adenocarcinoma: However, we propose a simpler evaluation strategy (pERK in adenocarcinoma, and nuclear p53 in squamous cell carcinoma) for prognostic biomarkers using immunohistochemistry, a technique routinely performed in clinics and feasible in one FFPE sample sheet and thus requiring a very limited amount of tissue.